Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Access Pharmaceuticals (AMEX:AKC)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Financials
Location
2600 Stemmons Freeway, Suite 176
Dallas, TX 75207
Phone: (214) 905-5100
Fax: (214) 905-5101
Email: axcs@accesspharma.com
Employees (last reported count): 16
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Historical Quote Data
 ·Free Annual Report
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Website
 ·Home Page

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 29%
·Institutional: 12% (17% of float)
(12 institutions)
·Net Inst. Buying: 832.0K shares (+34.91%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Access Pharmaceuticals, Inc. is a development-stage pharmaceutical company focused on developing both novel low-development risk product candidates, and technologies with longer-term major product opportunities. The Company has proprietary patents or rights to five technology platforms: synthetic polymers, bioerodible hydrogels, Residerm, carbohydrate-targeting technology and agents for the prevention and treatment of viral disease, including HIV. Its partner, GlaxoSmithKline is marketing Aphthasol in the United States, a drug jointly developed for the treatment of canker sores. The Company has licensed certain of the rights to amlexanox for the treatment of canker sores from GlaxoSmithKline for certain countries and the worldwide rights for additional indications, including mucositis and oral diseases. The Company is also developing Polymer Platinate, a chemotherapeutic agent believed to have significantly reduced toxicity and superior efficacy in treating cancers.
More from Market Guide: Expanded Business Description

Financial Summary
Access Pharmaceuticals provides drug delivery systems through the design of polymer/drug complexes to control site directed targeting, localized release and clearance of therapeutic drugs, imaging agents and radiopharmaceuticals. For the six months ended 6/30/01, revenues totaled $221 thousand vs. none. Net loss rose 6% to $2.7 million. Results reflect license revenues related to ResiDerm and amlexanox, offset by increased clinical development expenses for the OraRinse.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Pay

Herbert McDade, Jr., 74
Chairman
--  
Kerry Gray, 48
Pres, CEO
$411K
Stephen Thompson, 47
CFO, VP, Treasurer
126K
David Nowotnik, Ph.D., 52
VP R&D
260K
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc..
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- AMEX:AKCAs of 31-Aug-2001
Price and Volume
52-Week Low
on 20-Feb-2001
$2.15 
Recent Price$2.75 
52-Week High
on 3-Nov-2000
$9.50 
Beta0.59 
Daily Volume (3-month avg)20.6K
Daily Volume (10-day avg)32.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change-50.0%
52-Week Change
relative to S&P500
-32.9%
Share-Related Items
Market Capitalization$35.4M
Shares Outstanding12.9M
Float9.10M
Dividends & Splits
Annual Dividendnone 
Last Split: 1 for 20 on 18-June-1998
Per-Share Data
Book Value (mrq)$0.96 
Earnings (ttm)-$0.44 
Earnings (mrq)-$0.12 
Sales (ttm)$0.03 
Cash (mrq)$1.85 
Valuation Ratios
Price/Book (mrq)2.86 
Price/EarningsN/A 
Price/Sales (ttm)106.14 
Income Statements
Sales (ttm)$328.0K
EBITDA (ttm)-$5.76M
Income available to common (ttm)-$5.59M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-20.48%
Return on Equity (ttm)-38.06%
Financial Strength
Current Ratio (mrq)12.59 
Debt/Equity (mrq)1.09 
Total Cash (mrq)$23.8M
Short Interest
As of 8-Aug-2001
Shares Short7,000 
Percent of Float0.1%
Shares Short
(Prior Month)
7,000 
Short Ratio0.35 
Daily Volume20.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.